GeneDx (NASDAQ:WGS) reported third-quarter revenue of $123.1 million and raised its full-year profit outlook, but cut its test volume growth forecast. Adjusted gross margin was 72%, and adjusted net income was $8.6 million. New payer-documentation rules, meant to improve reimbursement, have slowed test starts and raised cancellations, downgrades and delays. Average reimbursement rose about 5% from the second quarter to $3,436 per test. The company now expects full-year adjusted gross margin of about 71% and adjusted net income of at least $12 million. It expects revenue at the low end of its $475 million–$490 million range. Management also expects a mid-single-digit revenue headwind in 2027 from the Protecting Access to Medicare Act.

GeneDx Q3 earnings call highlights. GeneDx (NASDAQ:WGS) reported third-quarter revenue of $123.1 million and raised its full-year profitability outlook, even as new documentation requirements led the genetic testing company to lower its expectations for test volume growth. Management said the company is requiring more payer documentation before genome testing begins, a change intended to improve reimbursement but one that has slowed the movement of some orders through the lab. Chief Executive Officer Katherine Stueland said demand remained strong and described the changes as part of a push toward profitable growth. GeneDx resulted more than 32,100 exome and genome tests in the quarter ended Sept. 30, 2026. Adjusted gross margin rose to 72%, while adjusted net income was $8.6 million. Reimbursement improvements slow test processing. GeneDx's blended average reimbursement rate increased approximately 5% from the second quarter to $3,436 per test. Chief Financial Officer Kevin Feeley attributed the improvement to better genome collections and a shift in the testing mix toward exome, which has a higher average contracted rate and reimbursement rate. President Mark Gardner said the company's review found that 62% of exome and genome denials were administrative or procedural, while the remaining 38% involved clinical necessity disputes or patients not covered by payer policies. Collecting documentation earlier can delay the start of testing and contributed to higher rates of order cancellations, downgrades and delayed starts, Gardner said. Accessions grew 28% year over year in the quarter, compared with 25% growth in reported test volume. During the question-and-answer session, Gardner said much of the gap reflected tests delayed by a few days rather than permanently lost volume. Feeley said he expected substantially all of the difference to move through the process over time, though not necessarily within one quarter. The underlying outpatient genome collection rate rose to 36% from 32% in the second quarter. The exome collection rate remained approximately 32%. Feeley said some of the genome improvement reflected health plans following Carelon's expanded coverage policy, while the contribution from Medi-Cal was smaller. Stueland said the documentation impact was concentrated among genetics customers, who are more likely to order genome tests. Feeley said orders received electronically, primarily through Epic, showed better document collection and reimbursement results than other orders. Profit outlook raised as volume growth forecast adjusted. GeneDx raised its full-year adjusted gross margin guidance to approximately 71% and its adjusted net income outlook to at least $12 million. It reaffirmed its revenue forecast of $475 million to $490 million but said it expected results at the low end of that range. The company adjusted its full-year exome and genome volume growth expectation to at least 28% and its exome and genome revenue growth expectation to at least 17%. For the fourth quarter, GeneDx projected total revenue of at least $135 million, including $121 million in exome and genome revenue on 34,500 resulted tests. It also forecast an average reimbursement rate of approximately $3,500 per test, adjusted gross margin of at least 71% and adjusted net income of approximately $12 million. Management did not provide formal 2027 guidance. Feeley said approximately 45% of total revenue is exposed to changes under the Protecting Access to Medicare Act, or PAMA, and that the company expects a mid-single-digit headwind to total revenue next year. He said improved collections could offset or more than offset that pressure. Genome costs and new markets in focus. Genome testing represented 26% of outpatient insurance-based volume in the third quarter, down from 32% in the second quarter. Feeley said the shift was deliberate near-term mix management, not an effort to minimize genome use. He expects genome's share to rise again as product enhancements and unit economics improve. Genome cost per test fell 43% from a year earlier, although it remained significantly higher than exome cost, Feeley said. The company sees a path to reduce genome cost per test by at least several hundred dollars over the next several quarters through lower reagent costs and, over a longer period, greater use of artificial intelligence and machine learning. GeneDx is also expanding beyond its core geneticist and pediatric neurologist customers. Gardner said the general pediatrician sales team, which entered the field in February, is already paying for itself. He clarified that management expects general pediatrics to contribute more unit volume growth in 2027 than any other individual segment, not more than all other segments combined. Gardner also said prenatal and neonatal intensive care markets were growing faster than the company overall. GeneDx recently launched an early-access program for long-read sequencing and is working with clinical experts on criteria for using the technology, he said. About GeneDx (NASDAQ:WGS). GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company's testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.

Mirum Pharmaceuticals has partnered with GeneDx Holdings to offer fully sponsored ExomeDx testing and genetic counselling for patients in its cholestasis, early-onset cataracts, and PBD-ZSD programmes. No insurance claims will be filed for eligible patients. The deal could raise GeneDx's test volumes, clinician contacts, and data collection in rare disease diagnostics without direct cost to patients. GeneDx currently reports a loss of $106.4 million on revenue of $454.4 million. Its near-term outlook still depends on reimbursement and collections, with outpatient realisation near 32% for genome claims. Payer cost controls or weak collection workflows remain the main risk. Analysts forecast revenue of $795.7 million and earnings of $29.2 million by 2029, based on 20.5% annual revenue growth.